CA2858379A1 - Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants - Google Patents

Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants Download PDF

Info

Publication number
CA2858379A1
CA2858379A1 CA2858379A CA2858379A CA2858379A1 CA 2858379 A1 CA2858379 A1 CA 2858379A1 CA 2858379 A CA2858379 A CA 2858379A CA 2858379 A CA2858379 A CA 2858379A CA 2858379 A1 CA2858379 A1 CA 2858379A1
Authority
CA
Canada
Prior art keywords
opn
seq
cancer
variant
relative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2858379A
Other languages
English (en)
French (fr)
Inventor
Susan R. Rittling
Peter Langborg WEJSE
Anja SERENA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arla Foods AMBA
ADA Forsyth Institute Inc
Original Assignee
Arla Foods AMBA
Forsyth Dental Infirmary for Children Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arla Foods AMBA, Forsyth Dental Infirmary for Children Inc filed Critical Arla Foods AMBA
Publication of CA2858379A1 publication Critical patent/CA2858379A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2858379A 2011-12-07 2012-12-07 Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants Abandoned CA2858379A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161567899P 2011-12-07 2011-12-07
US61/567,899 2011-12-07
US201261673912P 2012-07-20 2012-07-20
EP12177329 2012-07-20
US61/673,912 2012-07-20
EP12177329.5 2012-07-20
PCT/US2012/068628 WO2013086459A1 (en) 2011-12-07 2012-12-07 Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants

Publications (1)

Publication Number Publication Date
CA2858379A1 true CA2858379A1 (en) 2013-06-13

Family

ID=48574961

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2858379A Abandoned CA2858379A1 (en) 2011-12-07 2012-12-07 Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants

Country Status (12)

Country Link
US (1) US20150344534A1 (OSRAM)
EP (1) EP2788015A1 (OSRAM)
JP (1) JP2015500836A (OSRAM)
KR (1) KR20140104474A (OSRAM)
CN (1) CN104080472A (OSRAM)
AR (1) AR089136A1 (OSRAM)
AU (1) AU2012347468A1 (OSRAM)
BR (1) BR112014013565A2 (OSRAM)
CA (1) CA2858379A1 (OSRAM)
EA (1) EA201491010A1 (OSRAM)
WO (1) WO2013086459A1 (OSRAM)
ZA (1) ZA201404920B (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015001092A1 (en) * 2013-07-05 2015-01-08 Arla Foods Amba Mammalian milk osteopontin for enhancing immune responsiveness
EP4326758A4 (en) * 2021-04-20 2025-03-19 University of Cincinnati A vaccine adjuvant for infectious diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888552A (en) * 1988-04-29 1999-03-30 Immunotec Research Corporation Ltd. Anti-cancer therapeutic compositions containing whey protein concentrate
IL106576A (en) * 1992-08-13 2000-08-13 Immunotec Res Corp Ltd Anti-cancer therapeutic compositions for prophylaxis or for treatment of cancer
MXPA01010332A (es) * 1999-04-15 2002-09-18 Childrens Medical Center Metodos y composiciones para modular una respuesta inmunitaria.
PT1244702E (pt) * 2000-01-07 2006-08-31 Arla Foods Amba Processo para o isolamento da osteopontina do leite
NZ507335A (en) * 2000-10-05 2004-10-29 New Zealand Dairy Board Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP
NZ546398A (en) * 2003-09-18 2009-03-31 Arla Foods Amba Infant formula
SM200600031B (it) * 2006-10-06 2009-05-11 Gianluca Mech Integratore alimentare con attivatore proteico
WO2009052286A1 (en) * 2007-10-16 2009-04-23 Ventana Medical Systems, Inc. Grading, staging, and prognosing cancer using osteopontin-c

Also Published As

Publication number Publication date
JP2015500836A (ja) 2015-01-08
US20150344534A1 (en) 2015-12-03
AU2012347468A1 (en) 2014-06-26
BR112014013565A2 (pt) 2019-09-24
AR089136A1 (es) 2014-07-30
CN104080472A (zh) 2014-10-01
WO2013086459A1 (en) 2013-06-13
KR20140104474A (ko) 2014-08-28
EP2788015A1 (en) 2014-10-15
ZA201404920B (en) 2015-12-23
EA201491010A1 (ru) 2015-01-30

Similar Documents

Publication Publication Date Title
Liang et al. The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat
US10233221B2 (en) Peptide having eight amino acid sequences derived from cage and retaining anticancer activity and activity to promote anticancer drug sensitivity of anticancer drug-resistant cancer cells
KR20190059297A (ko) 고-이동성 군 박스 1 돌연변이체
JP6568095B2 (ja) プロ酵素及び酵素の混合物を含む医薬組成物
KR20080030559A (ko) 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의나트륨염 및 이것의 유도체를 함유하는 약학 조성물
CN111032075A (zh) 用于治疗癌症的方法和组合物
CN114588274A (zh) 一种负载cRGD和小分子抗肿瘤药物的复合外泌体及其制备方法和应用
CN108348563A (zh) 含有紫草根提取物作为有效成分的用于预防、改善或治疗周围神经病变的组合物
CN107949392B (zh) 用于生产含高含量af-16的蛋黄的方法
KR101377797B1 (ko) 미니-ＰＥＧ가 접합된 항-ｆｌｔ-1 펩타이드를 유효성분으로 함유하는 혈관신생 억제용 조성물
US20250213649A1 (en) Peptide having anti-inflammatory and anti-fibrotic activities and use thereof
KR102261371B1 (ko) CP2c 표적 펩티드 기반 항암제
CA2858379A1 (en) Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants
US20150190460A1 (en) Osteopontin peptide fragments for use in suppression or prevention of tumor growth
CN115634211B (zh) 一种人血清白蛋白为载体递送莲子心生物碱的纳米粒及其制法和应用
KR20140130495A (ko) 고셰병 치료용 경구형 단위 투약 형태 및 이의 용도
KR20110121072A (ko) 인체 내 암세포주에 대한 증식억제활성으로 피부암, 폐암, 자궁암 및 위암에 대해 항암효과를 갖는 조성물의 개발
CN105055318B (zh) 一种具有man和wga修饰的双重靶向脂质体及其制备方法和应用
CN113116940B (zh) 一种副干酪乳杆菌gmnl-346用于抗口腔癌之用途
CN119677524A (zh) 植物乳杆菌pdg8以及治疗心血管疾病的用途
US11331350B2 (en) Use of Mycobacterium paragordonae for cancer immunotherapy
Lu et al. Nanomedicine integrating the lipidic derivative of 5-fluorouracil, miriplatin and PD-L1 siRNA for enhancing tumor therapy
JP2022064275A (ja) 上皮細胞がんを治療する医薬組成物を調製するための小胞子霊芝の免疫調節タンパク質及びキーホールリンペットヘモシアニン及びその用途
KR101552021B1 (ko) Rab5 발현 저해 물질을 유효 성분으로 포함하는 파브리 질환의 예방 또는 치료용 조성물
EP4582458A1 (en) Micelle comprising amphiphilic peptide, and antigen carrier nanoparticle using same

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20181207